Ghent University

International Consortium Develops Revolutionary Platform to Predict Human Antibody Drug Responses

- An international research consortium led by VIB and Ghent University has developed a novel genetically engineered mouse model that accurately replicates human Fc gamma receptor biology, addressing critical limitations in antibody drug testing. - The platform solves the problem of species differences in immune responses that have led to costly late-stage clinical failures and unexpected safety issues, including dangerous blood clotting risks that were previously undetectable in standard preclinical models. - The new system enables head-to-head comparisons of antibody variants and provides more reliable early-stage data, potentially reducing development costs and accelerating delivery of effective treatments to patients. - Published in Science Immunology, this breakthrough aligns with FDA expectations for more sophisticated preclinical models and represents a collaboration between VIB-Ghent University, argenx, genOway, and Innate Pharma.